PMID- 37803144
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240311
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 38
IP  - 4
DP  - 2024 Mar
TI  - Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic 
      variations, pathogenic mechanisms and implications in management.
PG  - 659-667
LID - 10.1038/s41433-023-02764-w [doi]
AB  - Advances in imaging have led to improved ability to characterize variations in 
      clinical sub-phenotypes of macular neovascularization (MNV) in Age-related 
      macular degeneration (AMD). Polypoidal choroidal vasculopathy (PCV) was initially 
      described based on characteristic features observed in indocyanine green 
      angiography (ICGA) and was thought to be a distinct entity from AMD. However, 
      subsequent careful observations based on confocal scanning laser 
      ophthalmoscopy-based ICGA, optical coherence tomography (OCT) and OCT angiography 
      have led researchers to appreciate similarities between PCV lesion and type 1 MNV 
      in typical neovascular AMD. Concurrently, clinical trials have shown that 
      anti-VEGF monotherapy can achieve favourable visual outcome in the majority of 
      eyes with PCV. These learnings have led to a shift in the way PCV is managed over 
      the past decade. Recent studies have supported the use of non-ICGA based imaging 
      modality to screen for PCV and the adoption of anti-VEGF monotherapy as initial 
      therapy for PCV. A focus of recent research has been in the understanding of the 
      role of choroidal alterations in the pathogenesis of PCV. The concept of 
      pachychoroid in leading to outer retinal ischemia has garnered increasing 
      support. Future research in this area should evaluate the potential of choroidal 
      morphology in guiding personalized therapy in PCV.
CI  - (c) 2023. The Author(s).
FAU - Cheung, Chui Ming Gemmy
AU  - Cheung CMG
AUID- ORCID: 0000-0003-3358-3516
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore. gemmy.cheung.c.m@singhealth.com.sg.
AD  - Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS 
      Medical School, Singapore, Singapore. gemmy.cheung.c.m@singhealth.com.sg.
LA  - eng
GR  - NMRC/LCG/004/2018/MOH | National Medical Research Council (NMRC)/
PT  - Journal Article
PT  - Review
DEP - 20231006
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
MH  - Humans
MH  - *Choroidal Neovascularization/diagnosis/drug therapy/etiology
MH  - Polypoidal Choroidal Vasculopathy
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Fluorescein Angiography/methods
MH  - Vascular Endothelial Growth Factor A/therapeutic use
MH  - Visual Acuity
MH  - *Wet Macular Degeneration/drug therapy
MH  - Choroid/pathology
MH  - Biological Variation, Population
MH  - Tomography, Optical Coherence/methods
MH  - *Polyps/diagnosis/drug therapy/complications
MH  - Retrospective Studies
MH  - Indocyanine Green
PMC - PMC10920817
COIS- CMGC reports grants, personal fees and non-financial support from Bayer, Roche, 
      Boehringer Ingelheim, Zeiss, Novartis, Topcon, Iveric, Retimark.
EDAT- 2023/10/07 00:41
MHDA- 2024/03/11 06:42
PMCR- 2023/10/06
CRDT- 2023/10/06 23:28
PHST- 2023/08/30 00:00 [received]
PHST- 2023/09/18 00:00 [accepted]
PHST- 2023/09/07 00:00 [revised]
PHST- 2024/03/11 06:42 [medline]
PHST- 2023/10/07 00:41 [pubmed]
PHST- 2023/10/06 23:28 [entrez]
PHST- 2023/10/06 00:00 [pmc-release]
AID - 10.1038/s41433-023-02764-w [pii]
AID - 2764 [pii]
AID - 10.1038/s41433-023-02764-w [doi]
PST - ppublish
SO  - Eye (Lond). 2024 Mar;38(4):659-667. doi: 10.1038/s41433-023-02764-w. Epub 2023 
      Oct 6.